Conversely, inhibiting SPHK1 can sensitize CML and pancreatic cancer cells to the proapoptotic effects of imatinib and gemcitabine, respectively, apparently by reducing the S1P/ceramide ratio [40, 41]. Here, SPHK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.